Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2006 2
2007 1
2009 1
2010 2
2011 1
2012 1
2014 1
2019 1
2020 2
Text availability
Article attribute
Article type
Publication date

Search Results

11 results
Results by year
Filters applied: . Clear all
Page 1
Trimetazidine shortens QTc interval in patients with ischemic heart failure.
Zemljic G, Bunc M, Vrtovec B. Zemljic G, et al. J Cardiovasc Pharmacol Ther. 2010 Mar;15(1):31-6. doi: 10.1177/1074248409354601. Epub 2009 Dec 4. J Cardiovasc Pharmacol Ther. 2010. PMID: 19966175 Clinical Trial.
We analyzed the effects of trimetazidine on QTc interval in patients with ischemic heart failure. METHODS: A prospective trial included 42 patients with ischemic heart failure (New York Heart Association [NYHA] 2 or 3 …
We analyzed the effects of trimetazidine on QTc interval in patients with ischemic heart failure. METHODS: A prospectiv …
Effect of Trimetazidine Dihydrochloride Therapy on Exercise Capacity in Patients With Nonobstructive Hypertrophic Cardiomyopathy: A Randomized Clinical Trial.
Coats CJ, Pavlou M, Watkinson OT, Protonotarios A, Moss L, Hyland R, Rantell K, Pantazis AA, Tome M, McKenna WJ, Frenneaux MP, Omar R, Elliott PM. Coats CJ, et al. JAMA Cardiol. 2019 Mar 1;4(3):230-235. doi: 10.1001/jamacardio.2018.4847. JAMA Cardiol. 2019. PMID: 30725091 Free PMC article. Clinical Trial.
The trial included 51 drug-refractory symptomatic (New York Heart Association class ≥2) patients aged 24 to 74 years with a maximum left ventricular outflow tract gradient 50 mm Hg or lower and a peak oxygen consumption during exercise of 80% or less p …
The trial included 51 drug-refractory symptomatic (New York Heart Association class ≥2) patients aged 24 to 74 y …
Is treatment with trimetazidine beneficial in patients with chronic heart failure?
Zhou X, Chen J. Zhou X, et al. PLoS One. 2014 May 5;9(5):e94660. doi: 10.1371/journal.pone.0094660. eCollection 2014. PLoS One. 2014. PMID: 24797235 Free PMC article. Review.
BACKGROUND: Whether additional benefit can be achieved with the use of trimetazidine (TMZ) in patients with chronic heart failure (CHF) remains controversial. ...RESULTS: TMZ therapy was associated with considerable improvement in left ventricular ejec …
BACKGROUND: Whether additional benefit can be achieved with the use of trimetazidine (TMZ) in patients with chronic heart f
Trimetazidine: a meta-analysis of randomised controlled trials in heart failure.
Gao D, Ning N, Niu X, Hao G, Meng Z. Gao D, et al. Heart. 2011 Feb;97(4):278-86. doi: 10.1136/hrt.2010.208751. Epub 2010 Dec 5. Heart. 2011. PMID: 21134903 Review.
OBJECTIVE: To explore whether trimetazidine could improve symptoms, cardiac functions and clinical outcomes in patients with heart failure (HF). ...With trimetazidine therapy, left ventricular end-systolic volume was significantly reduced (WMD 10.37 ml …
OBJECTIVE: To explore whether trimetazidine could improve symptoms, cardiac functions and clinical outcomes in patients with heart
Additional use of trimetazidine in patients with chronic heart failure: a meta-analysis.
Zhang L, Lu Y, Jiang H, Zhang L, Sun A, Zou Y, Ge J. Zhang L, et al. J Am Coll Cardiol. 2012 Mar 6;59(10):913-22. doi: 10.1016/j.jacc.2011.11.027. J Am Coll Cardiol. 2012. PMID: 22381427 Free article. Review.
OBJECTIVES: The aim of this meta-analysis was to evaluate the effects of additional trimetazidine (TMZ) treatment on patients with chronic heart failure (CHF). ...Moreover, TMZ therapy was associated not only with the increase of left ventricular eject …
OBJECTIVES: The aim of this meta-analysis was to evaluate the effects of additional trimetazidine (TMZ) treatment on patients with ch …
Effects of metabolic modulation by trimetazidine on left ventricular function and phosphocreatine/adenosine triphosphate ratio in patients with heart failure.
Fragasso G, Perseghin G, De Cobelli F, Esposito A, Palloshi A, Lattuada G, Scifo P, Calori G, Del Maschio A, Margonato A. Fragasso G, et al. Eur Heart J. 2006 Apr;27(8):942-8. doi: 10.1093/eurheartj/ehi816. Epub 2006 Mar 1. Eur Heart J. 2006. PMID: 16510466 Clinical Trial.
New York Heart Association (NYHA) class, ejection fraction (EF), maximal rate-pressure product, and metabolic equivalent system (METS) were evaluated. ...CONCLUSION: Trimetazidine improves functional class and LV function in patients with hea
New York Heart Association (NYHA) class, ejection fraction (EF), maximal rate-pressure product, and metabolic eq
TrimetaziDine as a Performance-enhancING drug in heart failure with preserved ejection fraction (DoPING-HFpEF): rationale and design of a placebo-controlled cross-over intervention study.
van de Bovenkamp AA, Bakermans AJ, Allaart CP, Nederveen AJ, Kok WEM, van Rossum AC, Handoko ML. van de Bovenkamp AA, et al. Neth Heart J. 2020 Jun;28(6):312-319. doi: 10.1007/s12471-020-01407-z. Neth Heart J. 2020. PMID: 32162204 Free PMC article.
BACKGROUND: Currently, no specific treatment exists for heart failure with preserved ejection fraction (HFpEF). Left ventricular (LV) relaxation during diastole is a highly energy-demanding process, while energy homeostasis is known to be compromised in HFpEF. ...Th …
BACKGROUND: Currently, no specific treatment exists for heart failure with preserved ejection fraction (HFpEF). Left ventricul …
A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure.
Fragasso G, Palloshi A, Puccetti P, Silipigni C, Rossodivita A, Pala M, Calori G, Alfieri O, Margonato A. Fragasso G, et al. J Am Coll Cardiol. 2006 Sep 5;48(5):992-8. doi: 10.1016/j.jacc.2006.03.060. Epub 2006 Aug 17. J Am Coll Cardiol. 2006. PMID: 16949492 Free article. Clinical Trial.
OBJECTIVES: This study sought to assess whether the long-term addition of trimetazidine to conventional treatment could improve functional class, exercise tolerance, and left ventricular function in patients with heart failure (HF). ...Among the others, Ne
OBJECTIVES: This study sought to assess whether the long-term addition of trimetazidine to conventional treatment could improve funct …
Short- and long-term beneficial effects of trimetazidine in patients with diabetes and ischemic cardiomyopathy.
Fragasso G, Piatti Md PM, Monti L, Palloshi A, Setola E, Puccetti P, Calori G, Lopaschuk GD, Margonato A. Fragasso G, et al. Am Heart J. 2003 Nov;146(5):E18. doi: 10.1016/S0002-8703(03)00415-0. Am Heart J. 2003. PMID: 14597947 Clinical Trial.
BACKGROUND: Trimetazidine (TMZ) has been shown to partially inhibit free fatty acid oxidation by shifting substrate utilization from fatty acid to glucose. ...Among the others, New York Heart Association class, ejection fraction, exercise time, …
BACKGROUND: Trimetazidine (TMZ) has been shown to partially inhibit free fatty acid oxidation by shifting substrate utilization from …
Beneficial effects of trimetazidine treatment on exercise tolerance and B-type natriuretic peptide and troponin T plasma levels in patients with stable ischemic cardiomyopathy.
Di Napoli P, Di Giovanni P, Gaeta MA, D'Apolito G, Barsotti A. Di Napoli P, et al. Am Heart J. 2007 Sep;154(3):602.e1-5. doi: 10.1016/j.ahj.2007.06.033. Am Heart J. 2007. PMID: 17719313 Clinical Trial.
We investigated the effects of the metabolic agent trimetazidine (TMZ) on exercise tolerance and prognostic markers B-type natriuretic peptide (BNP) and cardiac troponin T (cTnT) plasma levels. ...RESULTS: After 6 months, no significant New York Heart
We investigated the effects of the metabolic agent trimetazidine (TMZ) on exercise tolerance and prognostic markers B-type natriureti …
11 results
Jump to page
Feedback